

10/530685

JCS Rec'd PCT/PTO 08 APR 2005

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q87415

Yoshiki SAKAI, et al.

Appln. No.: National Stage Entry of PCT/JP03/12981

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: April 08, 2005

Examiner: Unknown

For: ENDOGENEOUS REPAIR FACTOR PRODUCTION ACCELERATOR

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after


INFORMATION DISCLOSURE STATEMENT  
U.S. Appln. No.:

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of an English Language International Search Report from the International Searching Authority in the International Application, including at least that portion of the International Search Report indicating the degree of relevance found by the International Searching Authority, except for WO 01/72268, WO 99/09992 and WO 00/03980-- each of which has an English abstract on the first page. Also, Applicants advise that US Patent 4,479,966 corresponds to JP-A-54-130543. Applicants will supplement this IDS with respect to satisfaction of the concise explanation of relevance requirements for JP-A-2000-239188.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



Mark Boland  
Registration No. 32,197

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE  
23373  
CUSTOMER NUMBER

Date: April 8, 2005

Substitute for Form 1449 A &amp; B PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if known 10/530685

Application Number	National Stage Entry of PCT/JP03/12981
Confirmation Number	Unknown
Filing Date	April 08, 2005
First Named Inventor	Yoshiki SAKAI
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q87415

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US 4,479,966			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		WO	01/072268	A	10-04-2001	Toray Industries, Inc.	
		EP	1121939	A	08-08-2001	Pfizer Products Inc.	
		EP	1175891	A	01-30-2002	L'Oreal	
		WO	99/26629	A	06-03-1999	Allergan Sales, Inc.	
		WO	01/016132	A	03-08-2001	Fujisawa Pharmaceutical Co., Ltd.	
		JP	2000-239188	A	09-05-2000	Mitsubishi Chemical Corp.	
		WO	99/09992	A	03-04-1999	Mitsubishi Pharma Corp.	
		EP	581187	B	12-04-1996	Ono Pharmaceutical Co., Ltd.	
		EP	860430	A	06-23-1999	Ono Pharmaceutical Co., Ltd.	
		EP	169725	B	03-21-1990	Dainippon Pharmaceutical Co., Ltd.	
		JP	54-130543	A	10-09-1979	Ono Pharmaceutical Co., Ltd.	
		WO	00/003980	A	01-27-2000	Ono Pharmaceutical Co., Ltd.	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		Yoshitada SAKI et al., "Prostaglandin E2 Regulates the Expression of Basic Fibroblast Growth Factor Messenger RNA in Normal Human Fibroblasts," Kobe J. Med. Sci., vol. 47, no. 35/45, 2001, pages 35 to 44	
		Hiroshi SENO et al., "Cyclooxygenase 2-and Prostaglandin E <sub>2</sub> Receptor EP <sub>2</sub> -dependent Angiogenesis in Apc <sup>716</sup> Mouse Intestinal Polyps," Cancer Research, vol. 62, January 15, 2002, pages 506-511	
		International Search Report dated December 16, 2003	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.